18 results
8-K
EX-99.1
BPMC
Blueprint Medicines Corp
2 May 24
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
7:09am
Blueprint’s 2023 progress on environmental, social, and governance (ESG) initiatives and strategy and reflecting the results of a materiality
8-K
EX-10.1
BPMC
Blueprint Medicines Corp
25 May 23
Entry into a Material Definitive Agreement
4:32pm
respects (except that such materiality qualifier shall not be applicable to any representations or warranties that already are qualified or modified … as to “materiality” or “Material Adverse Effect” in the text thereof, which representations and warranties shall be true and correct in all respects
8-K
EX-2.1
s86ko2sxgo2mggn
30 Dec 21
Blueprint Medicines Completes Acquisition of Lengo Therapeutics
9:11am
8-K
afeot
30 Dec 21
Blueprint Medicines Completes Acquisition of Lengo Therapeutics
9:11am
8-K
ixc4sp3ls0 98ra5
29 Nov 21
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
7:04am
8-K
EX-1.1
a3ite
23 Jan 20
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
4:29pm
8-K
EX-1.1
s3dlt0gx
29 Mar 19
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock
4:24pm
10-K
EX-10.11
nkeroui9ctz q1xus
11 Mar 16
Annual report
12:00am
- Prev
- 1
- Next